XS
MRNA icon

XR Securities’s Moderna MRNA Stock Holding History

XR Securities’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,800
Closed -$405K – 294
2024
Q1 		$405K Sell
3,800
-3,100
-45% -$312K 0.01% 228
2023
Q4 		$686K Buy
6,900
+2,100
+44% +$177K 0.03% 228
2023
Q3 		$496K Sell
4,800
-2,700
-36% -$301K 0.04% 257
2023
Q2 		$911K Buy
7,500
+2,800
+60% +$374K 0.04% 166
2023
Q1 		$722K Sell
4,700
-4,900
-51% -$808K 0.02% 221
2022
Q4 		$1.72M Buy
+9,600
New +$1.57M 0.17% 115
2022
Q1 		– Sell
-35,200
Closed -$627K – 443
2021
Q4 		$627K Buy
35,200
+13,000
+59% +$3.8M 0.06% 76
2021
Q3 		$1.49M Buy
22,200
+13,600
+158% +$5.02M 0.69% 30
2021
Q2 		$678K Sell
8,600
-3,600
-30% -$643K 0.3% 57
2021
Q1 		$138K Sell
12,200
-12,700
-51% -$1.84M 0.01% 251
2020
Q4 		$378K Buy
+24,900
New +$2.52M 0.03% 110

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

XR Securities's MRNA Position: Q2 2024 in Review

XR Securities sold out of Moderna (MRNA) in Q2 2024, closing a stake of 1,880 shares — an estimated $200K sold.

XR Securities first reported a position in MRNA in Q4 2020 and held it in 11 quarters. The position peaked at $4.04M in Q4 2021. 955 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

  • XR Securities reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
  • XR Securities sold 1,880 Moderna shares in Q2 2024, an estimated $200K.
  • XR Securities first reported a position in Moderna in Q4 2020 and held it in 11 quarters.
  • XR Securities's Moderna position peaked at $4.04M in Q4 2021.
  • 955 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on XR Securities's 13F filing for Q2 2024, filed 5 Aug 2024.